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Abstract
Background: Majority of individuals with history of visceral leishmaniasis (VL) exhibit strong immunity to re-infection,
however, the mechanism of resistance is poorly understood. It is unclear whether CD8+ T cells contribute to protection
against Leishmania donovani infection through cytotoxic activity. The present study aims to evaluate immunological
mechanism associated with resistance to the disease in healed VL (HVL) individuals and further, the contribution of
CD8+ T cells in the protective immunity.
Methods: Peripheral blood mononuclear cells (PBMCs) from VL, HVL and naive groups were exposed in vitro to total
soluble Leishmania antigen (TSLA) from L. donovani. The proliferation index was determined by ELISA based
lymphoproliferative assay. Cytokines and granzyme B levels were measured by CBA. Activated T-cell populations
were estimated using flow cytometry.
Results: We observed significantly higher lymphoproliferation, cytokines and granzyme B levels in HVL group
compared to naive or VL group. More strikingly, we found a strong association (rs = 0.895, P < 0.0001) between
proliferation index (PI) and granzyme B level, with a significant proportion of activated CD8+ T cells in HVL group.
Conclusions: Leishmania immune group (HVL) exhibited durable and strong cellular immune response to TSLA in
terms of lymphoproliferation as well as production of Th1 cytokines and granzyme B. Additionally, the elevated
level of activated CD8+ T cells and stimulation of cytotoxic activity through granzyme B production, indicated a
possible role of CD8+ T cells in resistance to L. donovani infection in the HVL group.
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Background
Leishmaniasis is a neglected tropical disease which poses
risk to over 350 million people worldwide, in 98 coun-
tries or territories [1]. Depending on the species, the dis-
ease manifests into different clinical forms, ranging from
self-healing cutaneous leishmaniasis (CL) to disfiguring
mucosal lesions to the visceral form, visceral leishmania-
sis (VL). Of these, VL is the most severe form which
proves fatal if diagnosed late or left untreated. Currently,
more than 90% of annual incidence of VL occurs in
countries like India, Sudan, Bangladesh, Brazil, Ethiopia
and the Nepal [2,3]. In India, about 5–10% of apparently
healed VL patients develop an unusual dermal form of
the disease termed Post-kala azar dermal leishmaniasis
(PKDL) which constitutes an important reservoir for the
parasites [4].
Previous studies have shown that majority of individ-
uals who had VL or asymptomatic infection acquired
strong immunity against re-infection with the same sub-
species [5,6]. This observation strongly advocates the de-
velopment of an anti-leishmanial vaccine which could
induce a long lasting immunity similar to that acquired
naturally in healed visceral leishmaniasis (HVL) individ-
uals. However, understanding the immunological mechan-
ism associated with resistance and susceptibility to disease
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is of utmost importance for the design and evaluation of a
vaccine. This aspect is understudied in human VL al-
though several reports are available in murine models for
both CL and VL.
Immunopathology of human VL presents a mixed T-
helper 1 (Th1)/T-helper 2 (Th2) cytokine response, and is
characterized by the presence of a dominant Th2 response
over Th1 response. However, this response gets reversed
in HVL individuals with up regulation of Th1 response
[7,8]. The T lymphocyte profile of peripheral blood mono-
nuclear cells (PBMCs) of active VL patients have higher
proportion of CD8+ T cells compared to CD4+ T cells
which approach normal levels post-treatment [9,10]. Fur-
thermore, it was recently revealed that there is complete
anergic/exhaustion in CD8+ T cells in chronic VL patients,
with limited ability to contribute IFN-γ [11].
In experimental models, the role of CD8+ T cells in the
control of murine CL and determination of resistance to
re-infection remains contradictory. However, CD8+ T cells
have been thought to play a major role in murine VL.
CD8+ T cells participate not only in primary but also in
subsequent infection with Leishmania donovani [12]. One
study revealed that purified CD8+ T cells from the mice
infected with L. infantum expressed Th1 cytokines (IFN-γ
and TNF-α), and showed considerable cytotoxic activity
[13]. Another study in murine model suggested that L.
donovani escapes cellular responses by inducing ex-
haustion in CD8+ T cells [14], however, in canine VL,
both CD4+ and CD8+ T cells show Programmed Death-
1 mediated exhaustion, which impairs their phagocyte
function [15].
In human leishmaniasis, the role of CD8+ T cells is not
clear and depends largely on the species and the corre-
sponding disease. Limited studies have been carried out
with VL patients and ascribe a protective role for CD8+ T
cells, which is similar as in mice models. One earlier study
showed involvement of not only IFN-γ producing CD4+ T
cells, but also CD8+ T cells in the control of L. infantum
infection [16]. In human CL, the exact role of CD8+ T
cells is unclear. In a recent study, a major correlation was
observed between protection and the CD8+ T cells produ-
cing IFN-γ after re-stimulation [17]. In humans, several
studies suggest that CD8+ T cells mediate protection
through cytotoxicity against intracellular pathogens, such
as Trypanosoma cruzi and Mycobacterium tuberculosis
[18-20]. However, it is unclear whether CD8+ T cells con-
tribute protection against L. donovani parasites through
the cytotoxic activity.
In the present study, Leishmania-specific cellular im-
mune responses upon in vitro stimulation of PBMCs with
total soluble Leishmania antigen (TSLA) were evaluated
in VL, HVL and naive groups by measuring lymphoprolif-
eration, cytokines, granzyme B and the proportion of acti-
vated T cell populations. The data suggested the possible
role of effector CD8+ T cells in resistance to L. donovani
infection in HVL individuals.
Methods
Study subjects
Our study included active VL (n = 11), HVL (n = 16) and
naive (n = 19) individuals, all seronegative for HIV and
above sixteen years of age. Patients clinically diagnosed
with VL (age range in years, 17–62; age mean ± SD,
36.54 ± 14.37), were admitted to Department of Medicine,
Safdarjung Hospital, New Delhi. Active VL was diagnosed
with the clinical features such as fever, hepatosplenome-
galy, anaemia, weight loss, and pancytopenia and positive
rK39 strip test. VL was confirmed by presence of
Leishman-Donovan (LD) bodies and/or by PCR in bone
marrow aspirates. Individuals included in HVL group
(age range in years, 19–48; age mean ± SD 31.4 ± 9.19)
were healthy individuals that had completed VL treatment
at least one year back. The range of post-treatment dur-
ation for the HVL group was 1 to 20 yrs, with mean ± SD
11 ± 5.76 in yrs. They were all positive for rK39 strip test
and majority (15/16) were PCR negative. Blood samples of
19 naive individuals (age range, 18–35; age mean ± SD
26.89 ± 4.56) were included in this study. All naive individ-
uals were negative for rK39 strip test and for lymphopro-
liferative assay.
Ethics statement
The study was approved by and carried out under the
guidelines of the ethical committee of the Safdarjung
Hospital, India. All individuals under study provided
written informed consent for the collection of samples
and subsequent analysis.
Preparation of Total Soluble Leishmania antigen (TSLA)
Promastigotes of L. donovani (MHOM/IN/80/Ldd8Cl2)
were harvested in stationary phase, washed and the pel-
let resuspended in the lysing solution (50 mM Tris/5 mM
EDTA/HCl, pH7). After three cycles of freezing/thawing,
the samples were subjected to three pulses of 20 seconds
at 40 W with sonicator, at one minute interval. The sam-
ple was centrifuged at 5000 × g for 20 min at 4°C, and
supernatant was collected. Protein content was estimated
using Bradford method. TSLA was aliquoted and stored
at −80°C until further use.
Lymphoproliferative assay
PBMCs were isolated from the heparinised blood sam-
ples by density sedimentation (Ficoll-PaqueTM PLUS;
GE Healthcare), washed, resuspended in RPMI 1640 sup-
plemented with 10% FCS, penicillin (100 U/ml), and
streptomycin (100 μg/ml). PBMCs at concentration of
1 × 106 cells/ml were cultured in triplicate in 96-well flat-
bottom tissue culture plates (Axygen, Union city, CA,
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USA) and stimulated with TSLA (10 μg/ml) or PHA-M
(10 μg/ml) for 120 hrs in humidified 37°C/5% CO2
incubator. At 104–106 hrs incubation, 20 μL BrdU
labelling solution was added and samples reincubated
in humidified 37°C/5% CO2 incubator for another 16–
18 hrs. Lymphoproliferation was evaluated by commer-
cially available kit (BiotrakTM cell proliferation ELISA
system, version 2, GE Healthcare) using ELISA method.
The proliferation index (PI) was calculated as the ratio
of optical density (OD) of stimulated cultures and un-
stimulated cultures for each sample. Cell proliferation
was considered significant when PI was above cut-off
(mean + 3SD).
Estimation of cytokines and granzyme B in culture
supernatant
PBMCs of active VL, HVL and naive individuals were in-
cubated with TSLA for 120 hrs as described above. The
tissue culture plates were centrifuged and supernatants
were collected and stored at −80°C until use. Cytokines
(IFN-γ, TNF-α and IL-10) and granzyme B levels were
analysed by utilising cytometric bead array (CBA) flex sets
(BD Biosciences) and measuring fluorescence by flow
cytometry according to manufacturer’s recommenda-
tions. Samples were acquired on flow cytometer, BD
FACSCalibur using BD CellQuest Pro software and the
data were analysed using FCAP array software (BD Biosci-
ences). The assay sensitivity for IFN-γ, TNF-α, IL-10 and
granzyme B were 1.8, 1.2, 0.13 and 4 pg/ml respectively.
Flow cytometer analysis for cell surface phenotype of
activated T cell populations
Detection of activation in CD4+ or CD8+ T cells were
done by freshly isolated PBMCs (106/ml) from eight HVL
and eight naive individuals within recruited individuals for
this study, and incubated with TSLA (10 μg/ml) in a 96-
well flat-bottom plate for 120 hrs at 37°C. After 120 hrs,
the cells were harvested, washed with staining buffer
(0.02 M PBS, 1% FBS, and 0.01% sodium azide), and sur-
face stained with fluorochrome-conjugated antibodies to
CD3-FITC, CD4-PerCP-Cy5.5, CD8-PerCP-Cy5.5 and
CD69-APC, along with appropriate isotype controls (BD
Biosciences) for 30 min at 4°C. Cells were then washed
and finally suspended in 500 μl staining buffer (BD Biosci-
ences). Samples were acquired and analyzed on flow cyt-
ometer, BD FACSCalibur using BD CellQuest Pro
software on at least 10,000 events. Analysis gates were set
for lymphocytes using forward and side scatter properties
and the frequencies of activated CD4+ and CD8+ T cells
were acquired onCD3+ T cells. Cell viability using 7AAD
staining (BD) of a limited number of samples confirmed
that the gated lymphocytes were >99% viable for both
HVL and naive groups.
Statistical analysis
Results are represented as mean ± SE. Data were analysed
using GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA). Statistical significance were determined by
nonparametric Mann–Whitney test between two groups
and by Kruskal-Wallis test followed by the post hoc Dunn
multiple comparison test for more than two groups. Cor-
relation was calculated by Spearman rank correlation test.
The statistical tests were two-tailed and p values < 0.05
were considered significant.
Results
Proliferative response of peripheral lymphocytes to
L. donovani TSLA
Cell-Mediated Immune (CMI) response was analyzed in
terms of lymphoproliferative response in vitro to TSLA
and phytohemagglutinin (PHA). PHA served as positive
control and every individual of the three study group
showed high stimulation (Naive PI mean ± SE, 10.30 ±
3.649; VL, 7.73 ± 3.893; HVL, 11.30 ± 3.03). Every indi-
vidual in HVL group responded positively to TSLA and
the group mean (PI mean ± SE, 5.99 ± 0.497), was found
significantly high (p < 0.001) compared to naive group
(PI mean ± SE, 1.19 ± 0.064) or active VL (PI mean ± SE,
1.22 ± 0.124) (Figure 1). The response in active VL was
found comparable to naive group (p = 0.546).
Estimation of cytokines upon TSLA stimulation
PBMCs from active VL, HVL and naive groups were
screened for cytokines profile in response to TSLA
(Figure 2A-C). In HVL group, the CMI response (as
judged from the secretion of Th1 cytokines, IFN-γ and
TNF-α) was found significantly higher than the naive or
Figure 1 Lymphoproliferative response to TSLA in VL, HVL and
naive groups. Peripheral blood lymphocytes from individuals with
active VL (n = 11), HVL (n = 16) and naive (n = 19) groups were
incubated with TSLA (10 μg/ml) for 120 hrs and lymphoproliferation
was measured by BrdU incorporation for the last 12–14 hrs using
BiotrakTM cell proliferation ELISA system. Horizontal lines indicate
mean values. ***p < 0.001.
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active VL. HVL group (mean ± SE, 738.44 ± 206.21)
showed significantly high (p < 0.001) IFN-γ level com-
pared to naive (mean ± SE, 1.80 ± 0.57) or active VL
(mean ± SE, 10.63 ± 2.76). Cut off (Mean + 3SD) value for
IFN-γ was determined as 9.33 pg/ml and, importantly,
every HVL individual showed IFN-γ level above cut-off
value. Similarly, significantly high TNF-α production was
observed in response to TSLA stimulation in HVL group
(mean ± SE, 37.71 ± 9.59) compared to naive (mean ± SE,
1.01 ± 0.43, p < 0.001) or active VL (mean ± SE, 3.77 ±
2.33, p < 0.01). For IL-10 cytokine, the measured values for
HVL (mean ± SE, 2 ± 0.63) were low, and comparable to
naive, (mean ± SE, 0.66 ± 0.33) or active VL (mean ± SE,
0.69 ± 0.19).
Granzyme B analysis
Granzyme B, a serine proteinase produced by the cyto-
toxic lymphocytes, notably, induces rapid cellular death of
the target by apoptosis. Here, granzyme B was measured
in culture supernatant upon in vitro TSLA stimulation of
PBMCs. The granzyme B level of HVL group (mean ± SE,
1411.91 ± 441.62), was found significantly high compared
to naive (mean ± SE, 11.79 ± 3.98, p < 0.001) or active VL
group (mean ± SE, 45.97 ± 18.08, p < 0.01), with 11/12
(92%) HVL individuals showing values above cut off value
(58.10 pg/ml) (Figure 2D). Mean of active VL group was
found comparable to naive (p = 0.371).
Correlation between granzyme B level and proliferation
index
The secretion of granzyme B upon TSLA stimulation
were analysed in active VL, HVL and naive group with
the respective proliferation index. In HVL group, the
level of granzyme B was found strongly correlated with
PI (rs = 0.895, p < 0.0001) (Figure 3). Besides, we ob-
served moderately significant correlation between PI and
IFN-γ and TNF-α with rs = 0.63 (p = 0.03) and rs = 0.62
(p = 0.03) respectively in HVL group. However, we did
not observe any significant correlation between gran-
zyme B and IFN-γ level (rs = 0.434, p = 0.158) in the cul-
ture supernatant.
Estimation of activated T lymphocytes
The strong association between PI and granzyme B in the
HVL group, provided lead for the possible protective role
of CD8+ T cells. Therefore, using CD69 as a marker of ac-
tivation [21], we investigated the percentage of activated
CD4+ and CD8+ T cell populations upon in vitro TSLA
stimulation both in HVL and naive groups. CD8+ T cells
showed a pronounced activation in HVL, with signifi-
cantly higher percentage of CD8+CD69+ T cell population
in HVL group (mean ± SE, 7.99 ± 0.91, p = 0.0002) com-
pared to naive group (mean ± SE, 0.67 ± 0.19). There was
also a significantly higher percentage of CD4+CD69+ T cell
Figure 2 In vitro Leishmania-specific cellular immune response in VL, HVL and naive groups. PBMCs were isolated and incubated with TSLA
(10 μg/ml) for 120 hrs. (A-C) Cytokines (IFN-γ, TNF-α and IL-10) were measured in the supernatant of VL (n = 11), HVL (n = 16) and naive (n = 19) and
(D) Granzyme B were analyzed in the supernatant of VL (n = 11), HVL (n = 12) and naive (n = 16) using CBA. Horizontal lines indicate mean values. NS,
Not Significant, **p < 0.01, ***p < 0.001.
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(mean ± SE, 3.12 ± 0.44, p = 0.0047) in HVL compared to
naive group (mean ± SE 0.46 ± 0.07) (Figure 4).
Discussion
In the present study, we initially evaluated CMI response
in terms of lymphoproliferation upon in vitro TSLA
stimulation in active VL, HVL and naive groups. We dem-
onstrated significantly high lymphoproliferation in Leish-
mania immune group (HVL) implying the presence of
circulating Leishmania-specific memory T cells which
showed significantly higher lymphoproliferation compared
to that in unexposed individuals (naive). On the contrary,
active VL group failed to show lymphoproliferation which
indicated immune dysfunction [11,22]. Besides, earlier
studies investigated cellular immune responses in HVL in-
dividuals with short VL history (up to 1 year) [11,23,24]
whereas the present study included individuals with long
history of VL (1 to 20 yrs, mean ± SD, 11 ± 5.76 yrs) with
all cases showing PI values well above cut-off, indicating
Figure 3 Comparative assessment of granzyme B level and
proliferation index upon TSLA stimulation of PBMCs in HVL (n = 12)
group. Correlation was calculated by Spearman rank correlation test.
Diagonal line represents the best fit line.
Figure 4 Estimation of activated T lymphocytes. (A) Percentage of TSLA-activated CD4+ and CD8+ T cells in HVL and naive groups. PBMCs from
HVL (n = 8) and naive (n = 8) were incubated with TSLA (10 μg/ml) for 120 hrs at 37°C. The values of unstimulated cells were substracted from TSLA
stimulated cells. (B) Data showing representative FACS analysis in one each from HVL and naive individuals. Analysis gates were set for lymphocytes
using forward and side scatter properties and the frequencies of activated CD4+ and CD8+cells were acquired on CD3+ T cells. (C) Cell viability test
using 7AAD staining was done and the data show a representative FACS analysis in one of HVL individuals. Horizontal lines indicate mean values.
*p < 0.05, **p < 0.01.
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that an anti-leishmanial vaccine could provide long term
protection to Leishmania infection.
The cytokine analysis constitutes an important part
since they form a complex network of synergistic and an-
tagonistic interactions which not only induce but also
control immune response. IFN-γ, produced predominantly
by activated CD4 Th1 and CD8 cytotoxic T lymphocyte
(CTL) and NK cells in response to IL-12 signaling, is
an important activator of macrophages that enhances
their microbicidal activity against intracellular patho-
gens [25,26]. It promotes NO production by inducing
iNOS (inducible nitric oxide synthase) expression by in-
fected phagocytes thus facilitating elimination of parasites
and resolving Leishmania infection [27]. Another Th1
cytokine, tumor necrosis factor alpha (TNF-α), known to
exert cytotoxic effects on pathogens, has been closely as-
sociated with VL pathogenesis, being low in active VL and
getting restored after treatment [28]. The cytokine profile
upon TSLA stimulation of PBMCs corroborates our lym-
phoproliferation data. The production of significantly
higher level of Th1 cytokines (IFN-γ and TNF-α) to TSLA
was observed in HVL group compared to naive or active
VL group and is in accordance with earlier studies
[29-31]. The significant association between PI and IFN-γ
and TNF-α in HVL group indicates the strong CMI in in-
dividuals with prior exposure to Leishmania antigens. As
expected, no protective immune response was observed in
naive individuals while the active VL group exhibited per-
ipheral lymphocytes anergy [22]. IL-10 on the other hand
has counter regulatory role against IL-12 and IFN-γ and
thus favours the survival of Leishmania parasites by inhi-
biting NO-mediated killing [32]. We observed no signifi-
cant difference in IL-10 production between the different
study groups.
There are mainly two mechanisms by which cytotoxic
cells lyse their targets: the perforin-granzyme B path-
way and death receptors (Fas/FasL) [33,34]. The FasL-
dependent pathway utilises Fas surface receptor by Fas
ligand expressed on the surface of the CTL and NK
Cells, which triggers Fas-mediated apoptosis in target
cells. The chief mechanism used by cytotoxic cells to
induce target cell death is through the granule exocyt-
osis pathway and depends on the concerted action of
effector molecules contained in the cytolytic granules.
These granules contain perforin, the pore-forming mol-
ecule, together with granule-associated enzymes. Among
them, granzyme B is the most important effector molecule
for target-cell apoptosis [35]. It is unclear whether CD8+
T cells contribute protection against L. donovani parasites
through their cytotoxic activity. Limited studies have been
conducted dealing with parasite-specific cell-mediated
cytotoxicity in VL, CL or mucocutaneous leishmaniasis
[31,36-38]. Here, we evaluated granzyme B level to in-
vestigate whether individuals healed after L. donovani
infection develops a cytotoxic immune response upon re-
exposure. We demonstrated significantly higher granzyme
B level upon TSLA stimulation in Leishmania immune
(HVL) group compared to naive or VL group, with a
strong association between PI and granzyme B level.
Previous studies with viral infections have shown that
granzyme B is predominantly secreted by CD8+ T cells
[39], although, the contributions of NK cells and CD4+
cytotoxic cells have also been suggested [40,41]. Fur-
thermore, we observed a significantly high percentage
of CD8+CD69+ and CD4+CD69+ T cells in the healed VL
individuals. This is distinct from the report in cured CL
individuals where a high CD4+CD69+ T cells was demon-
strated to be responsible for the immunity to L. major
infection [31].
Conclusion
The study brings forth some essential points regarding
the immunological mechanism associated with resist-
ance to VL in healed VL individuals with long history of
VL. The preponderance of CD8+ T cells was suggested
in resistance to L. donovani infection possibly via the
perforin-granzyme B pathway and by the activation of
significant proportion of CD8+ T cell populations. The
findings support the role of CD8+ T cells in resistance to
Leishmania infection, which could be exploited for the
design and evaluation of a vaccine.
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